Investigational drug · Phase 3
NXC-201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Light Chain (AL) Amyloidosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "NXC-201"
First trial start
2027
Jan 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NXC-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Light Chain (AL) Amyloidosis
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "NXC-201" as an intervention, largest first.
- A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisPivotal-lookingNot yet recruiting
Nexcella Inc.Industry
NCT07709715 · 260 participants (planned) · Start Jan 2027 · Primary completion Dec 2028
Drug: NXC-201; Dara-CyBorD · For: Light Chain (AL) Amyloidosis
Polina StepenskyAcademic, hospital or other
NCT06971380 · 180 participants (planned) · Start Mar 1, 2025 · Primary completion May 15, 2028
Drug: HBI0101 CART · For: Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed; Light Chain Amyloidosis
Sites: Jerusalem, Israel
- NXC-201 (Formerly HBI0101) Multiple MyelomaActive, not recruiting
Hadassah Medical OrganizationAcademic, hospital or other
NCT04720313 · 160 participants (planned) · Start Jan 1, 2021 · Primary completion Jan 2027
Drug: NXC-201 (formerly HBI0101) · For: Dose Escalation and Safety
Sites: Jerusalem, Israel
- Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisActive, not recruiting
Nexcella Inc.Industry
NCT06097832 · 45 participants (planned) · Start Jun 5, 2024 · Primary completion Dec 2026
Drug: NXC-201 CAR-T · For: Light Chain (AL) Amyloidosis
Sites: Berkeley, California; Duarte, California; Los Angeles, California · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.
Vural E, Beksac M · Turk J Haematol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.